

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

B6.129P2-Trp53^{tm1Brn}/J

RRID:IMSR_JAX:008462

Type: Organism

Proper Citation

RRID:IMSR_JAX:008462

Organism Information

URL: <https://www.jax.org/strain/008462>

Proper Citation: RRID:IMSR_JAX:008462

Description: Mus musculus with name B6.129P2-Trp53^{tm1Brn}/J from IMSR.

Species: Mus musculus

Notes: gene symbol note: transformation related protein 53; congenic strain: Trp53

Affected Gene: transformation related protein 53

Genomic Alteration: targeted mutation 1; Anton Berns

Catalog Number: JAX:008462

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: B6.129P2-Trp53^{tm1Brn}/J

Record Creation Time: 20250513T053709+0000

Record Last Update: 20260725T044420+0000

Ratings and Alerts

No rating or validation information has been found for B6.129P2-Trp53^{tm1Brn}/J.

No alerts have been found for B6.129P2-Trp53^{tm1Brn}/J.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 138 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Diaz-Jimenez A, et al. (2026) EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis. *Cancer discovery*, 16(1), 46.

Zhang ZD, et al. (2026) MITA/STING-driven CD38 induction in Siglec-Flow macrophages promotes regulatory T cell survival and non-small cell lung cancer progression. *Developmental cell*.

Cheung JF, et al. (2025) Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas. *Cancer cell*, 43(12), 2311.

Hu K, et al. (2025) Development and Application of MiMouse, a Comprehensive Genomic Profiling Panel for Credentialing Mouse Tumor Models. *Cancer research communications*, 5(10), 1910.

Nguyen KA, et al. (2025) Activation of PI3K and deletion of p53 in keratin 15-expressing mouse mammary cells induces tumor heterogeneity and plasticity modeling metaplastic breast cancer. *The Journal of pathology*, 267(2), 213.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.

Park JS, et al. (2025) L1CAM signaling through planar cell polarity generates SOX2 + metastatic progenitors in lung adenocarcinoma. *bioRxiv : the preprint server for biology*.

Lee JY, et al. (2025) Senolytic-sensitive p16Ink4a+ fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. *Cell stem cell*, 32(12), 1869.

Guo J, et al. (2025) KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy. *Cancer cell*, 43(7), 1261.

Rominger MC, et al. (2025) Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state. *Cell reports*, 44(10), 116185.

Teng M, et al. (2025) Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation. *Cancer cell*, 43(5), 891.

Nguyen DT, et al. (2025) Protein kinase C γ dictates tumor trajectory, cell plasticity, and immune surveillance in lung adenocarcinoma. *Cell reports*, 44(12), 116606.

Mozzarelli AM, et al. (2025) RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma. *Cancer research*, 85(17), 3196.

Broderick C, et al. (2025) A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. *Cancer discovery*, 15(8), 1717.

Jang J, et al. (2025) Deciphering Precursor Cell Dynamics in Esophageal Preneoplasia via Genetic Barcoding and Single-Cell Transcriptomics. *bioRxiv : the preprint server for biology*.

Tang Z, et al. (2025) A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression. *Developmental cell*, 60(3), 379.

Yang C, et al. (2025) KRAS4B oncogenic mutants promote non-small cell lung cancer progression via the interaction of deubiquitinase USP25 with RNF31. *Developmental cell*, 60(12), 1768.

Salmerón C, et al. (2025) Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. *The Journal of pharmacology and experimental therapeutics*, 392(5), 103573.

Fraire CR, et al. (2025) An imbalance between proliferation and differentiation underlies the development of microRNA-defective pineoblastoma. *Genes & development*, 39(11-12), 727.

Hirade K, et al. (2025) Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy. *Cell reports. Medicine*, 6(9), 102317.